University of California Davis Comprehensive Cancer Center
Sacramento, CA
Accepting patients
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- Allogeneic Stem Cell Transplant
- Phase 1
Accepting patients
Venetoclax in Combination With ASTX727
Venetoclax in Combination With ASTX727, an All-Oral Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN With Excess Blasts (VICTORY-MDS/MPN): A Randomized, Phase 2 Trial
- BCL-2 Inhibitor
- Hypomethylating Agents (HMA)
- Phase 2